Studies on the paradoxical phase of sleep in the cat.

T. Tokizane

DOI: https://doi.org/10.1016/S0079-6123(08)64233-8

Progress in Brain Research

Abstract:

What problem does this paper attempt to address?

Pressurized Intraperitoneal Aerosol Chemotherapy for Peritoneal Carcinomatosis in Colorectal Cancer Patients: A Systematic Review of the Evidence

Marwan-Julien Sleiman,Annamaria Jelip,Nicolas Buchs,Christian Toso,Emilie Liot,Thibaud Koessler,Jeremy Meyer,Guillaume Meurette,Frederic Ris

DOI: https://doi.org/10.3390/cancers16213661

2024-10-30

Cancers

Abstract:Introduction: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) consists of the administration of aerosolized chemotherapy into the abdominal cavity of patients suffering from peritoneal carcinomatosis. Our aim was to review the evidence supporting PIPAC in patients with peritoneal carcinomatosis from colorectal cancer. Methods: A systematic review was performed in accordance with the 2020 PRISMA guideline. MEDLINE and CENTRAL were searched using combinations of terms including "Peritoneal carcinomatosis", "Peritoneal metastasis", "PIPAC", "Pressurized intraperitoneal aerosol chemotherapy" and "Colorectal cancer". Original studies, in English, including patients treated with PIPAC for colorectal peritoneal carcinomatosis, were considered eligible. Case reports, non-English or French language articles and secondary analyses were excluded. Results: A total of 385 articles were screened and 374 articles were excluded, leaving 11 publications for inclusion in the qualitative analysis. The included studies totalized 949 patients who received PIPAC for peritoneal carcinomatosis due to colorectal cancer. The median peritoneal carcinomatosis index (PCI) ranged from 10 to 31. In all studies, the complete PIPAC protocol was achieved with an average of two to three 3 PIPAC sessions per patient. Oxaliplatin (OX) was used as a chemotherapeutic agent in all studies and could be associated with intravenous 5-FU and leucovorin. Most post-operative adverse events were recorded as mild to moderate with no intraoperative complications. Only four studies reported a decrease in the average PCI score for 50% of the patients. Median overall survival ranged from 8 to 37.8 months. Quality of life indicators were stable between PIPAC-OX cycles with a small but not statistically significant trend of improvement of most functional scales. Conclusions: PIPAC for peritoneal carcinomatosis from colorectal origin is feasible, safe and tolerable. Its impact on survival outcomes or quality of life remains to be demonstrated by randomized trials.

oncology
PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases

Guowei Kim,Lyn Tan,Raghav Sundar,Bettina Lieske,Cheng Ean Chee,Jingshan Ho,Asim Shabbir,Maria V. Babak,Wee Han Ang,Boon Cher Goh,Wei Peng Yong,Lingzhi Wang,Jimmy B.Y. So,Hon Lyn Tan

DOI: https://doi.org/10.1158/1078-0432.ccr-20-2152

IF: 13.801

2020-11-04

Clinical Cancer Research

Abstract:Abstract Purpose: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel laparoscopic, intraperitoneal chemotherapy delivery technique aiming to improve drug distribution and tissue penetration to treat peritoneal metastases. Thus far, PIPAC oxaliplatin is conducted at an arbitrary dose of 92 mg/m2. We conducted a phase I study to establish safety and tolerability. Patients and Methods: We used a 3+3 dose-escalation design of PIPAC oxaliplatin for patients with peritoneal metastases from gastrointestinal tumors, after failure of at least first-line chemotherapy. Dose levels were planned at 45, 60, 90, and 120 mg/m2. Results: This study included 16 patients with 24 PIPAC procedures (8 gastric; 5 colorectal; and 1 gallbladder, pancreas, and appendix cancer each). Median age and peritoneal cancer index (PCI) score were 62 years and 17, respectively. Two patients developed pancreatitis (grade 2 and 3) at 45 mg/m2, necessitating cohort expansion. Another patient developed grade 2 pancreatitis at 90 mg/m2. There were no other dose-limiting toxicities, and the highest-dose cohort (120 mg/m2) tolerated PIPAC well. Pharmacokinetic analyses demonstrated good linearity between dose and maximum concentration (r2 = 0.95) and AUC (r2 = 0.99). On the basis of RECIST, 62.5% and 50% had stable disease after one and two PIPAC procedures, respectively. A total of 8 patients underwent two PIPAC procedures, with improvement of median PCI and peritoneal regression grade score from 15 to 12 and 2.5 to 2.0, respectively. Conclusions: The recommended phase II dose is 120 mg/m2. Future studies should further delineate the efficacy and role of PIPAC oxaliplatin for peritoneal metastases. See related commentary by de Jong et al., p. 1830

oncology
Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) experience in patients with recurrent low grade serous ovarian carcinoma (LGSOC): sub-cohort report of phase 1 clinical trial

Brad Nakamura,Rosemary Senguttuvan,Nora H Ruel,Paul H Frankel,Susan E Yost,Sarah Cole,Sue Chang,Alexander Jung,Melissa Eng,Raechelle Tinsley,Daphne Stewart,Edward Wang,Joshua Cohen,Jeannine Villella,Richard L Whelan,Amit Merchea,Danielle K DePeralta,Mihaela Cristea,Mark T Wakabayashi,Mustafa Raoof,Thanh Hue Dellinger

DOI: https://doi.org/10.3389/fonc.2024.1404936

2024-08-01

Abstract:Introduction: Low grade serous ovarian carcinoma (LGSOC) is a rare subtype of ovarian cancer (OC) that is challenging to treat due to its relative chemoresistance. Given that LGSOC patients often recur in the peritoneal cavity, novel intraperitoneal (IP) chemotherapy should be explored. Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) is a method that has demonstrated peritoneal disease control in cancers with peritoneal metastases. Methods: NCT04329494 is a US multicenter phase 1 trial evaluating the safety of PIPAC in recurrent ovarian, uterine, and GI cancers with peritoneal metastases. This analysis describes the outcomes of a sub-cohort of four LGSOC patients treated with IP cisplatin 10.5 mg/m2, doxorubicin 2.1 mg/m2 PIPAC q4-6 weeks. Primary endpoints included dose-limiting toxicities (DLT) and incidence of adverse events (AE). Secondary endpoints were progression free survival (PFS) and treatment response based on radiographic, intraoperative, and pathological findings. Results: Four patients with LGSOC were enrolled of which three were heavily pretreated. Median prior lines of therapy was 5 (range 2-10). Three patients had extraperitoneal metastases, and two patients had baseline partial small bowel obstructive (SBO) symptoms. Median age of patients was 58 (38-68). PIPAC completion rate (≥2 PIPACs) was 75%. No DLTs or Clavien-Dindo surgical complications occurred. No G4/G5 AEs were observed, and one G3 abdominal pain was reported. One patient had a partial response after 3 cycles of PIPAC and completed an additional 3 cycles with compassionate use amendment. Two patients came off study after 2 cycles due to extraperitoneal progressive disease. One patient came off study after 1 cycle due to toxicity. Median decrease in peritoneal carcinomatosis index between cycles 1 and 2 was 5.0%. Ascites decreased in 2 out of 3 patients who had ≥2 PIPACs. Median PFS was 4.3 months (1.7-21.6), median overall survival was 11.6 months (5.4-30.1), and objective response rate was 25%. Conclusion: PIPAC with cisplatin/doxorubicin is well tolerated in LGSOC patients without baseline SBO symptoms. IP response was seen in 2 out of 3 patients that completed ≥2 PIPAC cycles. Further study of PIPAC for patients with recurrent disease limited to the IP cavity and with no partial SBO symptoms should be considered.
Feasibility, Efficacy and Safety—A Systematic Review and Meta-Analysis

Francisca Ramalho-Vasconcelos,Raquel Gomes,Raquel Bouça-Machado,Marisa Aral,Jorge Nogueiro,Tiago Bouça-Machado,Bernardo Sousa-Pinto,Hugo Santos-Sousa

DOI: https://doi.org/10.3390/jcm13113320

IF: 3.9

2024-06-04

Journal of Clinical Medicine

Abstract:Background: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) is an emerging technique for delivering chemotherapy directly to the peritoneum via a pressurized aerosol. Its growing attention stems from its effectiveness in treating peritoneal carcinomatosis (PC) originating from various primary tumors, with gastric cancer (GC) being among the most prevalent. This study aimed to systematically investigate PIPAC's therapeutic role in gastric cancer peritoneal metastasis (GCPM). Methods: The systematic review and meta-analysis followed the PRISMA 2020 guidelines, searching Pubmed, Web of Science, and SCOPUS databases. The meta-analysis of relative risks and mean differences compared patients undergoing one or two PIPAC sessions with those completing three or more, assessing various outcomes. Results: Eighteen studies underwent qualitative analysis, and four underwent quantitative analysis. Patients with three or more PIPAC procedures had shorter hospital stays (MD = −1.2; 95%CI (−1.9; −0.5); p < 0.001), higher rates of histopathological response (RR = 1.77, 95%CI 1.08; 2.90; p = 0.023), and significantly improved overall survival (MD = 6.0; 95%CI 4.2; 7.8; p < 0.001). Other outcomes showed no significant differences. Conclusions: PIPAC demonstrated efficacy in carefully selected patients, enhancing histopathologic response rates and overall survival without prolonging hospital stays. This study underscores the necessity for randomized controlled trials and precise selection criteria to refine PIPAC's implementation in clinical practice.

medicine, general & internal
Impact of PIPAC-Oxaliplatin on Functional Recovery, Good Days, and Survival in a Refractory Colorectal and Appendiceal Carcinomatosis: Secondary Analysis of the US PIPAC Collaborative Phase 1 Trial

Muhammad Talha Waheed,Nora Ruel,Richard L. Whelan,Marwan Fakih,Yuman Fong,Danielle Deperalta,Amit Merchea,Virginia Sun,Robert Krouse,Thanh H. Dellinger,Mustafa Raoof

DOI: https://doi.org/10.1245/s10434-024-15980-9

IF: 4.339

2024-09-14

Annals of Surgical Oncology

Abstract:Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) is a novel, minimally invasive, safe, and repeatable method to treat carcinomatosis. Evidence regarding the clinical benefit (quality of life and survival) of PIPAC compared with that of conventional standard therapy (ST) is lacking.

oncology,surgery
PIPAC in patients with peritoneal metastases from gastrointestinal tract (PIPOX01): An open label, non-comparative phase 1/2 dose escalation and expansion trial

Frédéric Dumont,Vahan Kepenekian,Christophe Passot,Anne-Cécile Ezanno-Manasterski,Marc Pocard,Jean-Luc Raoul,Bénédicte Lelièvre,Sandrine Hiret,Hélène Senellart,Francois Pein,Judith Raimbourg,Loic Campion,Emilie Thibaudeau,Julie Paul,Olivier Glehen,BIG-RENAPE Networks

DOI: https://doi.org/10.1016/j.ejso.2024.108468

Abstract:Background: Despite modern systemic chemotherapy, survival remains poor for patients with advanced isolated peritoneal metastases from the gastrointestinal tract. We aimed to assess the safety and efficacy of pressurized intraperitoneal aerosol chemotherapy (PIPAC) with oxaliplatin. Patients and methods: We conducted a phase 1/2, open label, non-comparative, dose escalation and expansion trial of PIPAC with oxaliplatin in patients with a peritoneal cancer index (PCI) of more than 5, 13 and 15 for respectively a gastric, small bowel and colorectal primary cancer, and who had received at least three months of systemic chemotherapy. PIPAC cycle lengths were 4-6 weeks with systemic chemotherapy allowed 15 days after each PIPAC. PCI and oxaliplatin tumor concentration were assessed every PIPAC cycle. The main endpoints were tolerability, tumor response, and survival. Results: Between 2017 and 2020, 34 patients were enrolled in three centers, in this phase 1/2 study, of whom 25 were evaluable at the recommended dose determined in the phase I trial (90 mg/m2 plus systemic 5-FU). Before inclusion, patients received a median of 2 [1-4] chemotherapy lines and had a median PCI of 22.5 [7-29]. At this dose, the safety profile showed acceptable tolerability. Eight patients (32 %) had grade 3/4 treatment-related adverse events. Minor (grade 1/2) adverse events were mainly abdominal pain (n = 19, 76 %) and nausea (n = 16, 64 %). Median PFS was 6.1 months and median OS was 13 months. Conclusion: In patients with advanced and refractory peritoneal metastasis, PFS of 6.1 months is encouraging. A prospective randomized phase II study is required.
PIPAC Pharmacologic and Clinical Data

Delia Cortés‐Guiral,Onno Kranenburg,Olivia Sgarbura,Kurt Van Der Speeten,Albdelkader Taibi,Martin Hübner,Almog Ben Yacoov

DOI: https://doi.org/10.1002/jso.27900

2024-09-25

Journal of Surgical Oncology

Abstract:Pressurized intraperitoneal aerosol chemotherapy (PIPAC) emerged as an innovative intraperitoneal chemotherapy delivery system to overcome the issue of limited efficacy of systemic therapies to induce response in peritoneal malignancies. Promising results for patients with mesothelioma peritonei and peritoneal metastasis from gastric, ovarian, colorectal, pancreatic, and hepatobiliary tumors origin are changing the landscape for patients otherwise just facing palliative treatment. Ongoing trials will shed more light on the actual benefits of PIPAC.

oncology,surgery
Pressurised Intraperitoneal Aerosolised Chemotherapy—Results from the First Hundred Consecutive Procedures

David Hoskovec,Zdeněk Krška,Michal Vočka,Soňa Argalácsová,Petr Dytrych

DOI: https://doi.org/10.3390/cancers16081559

2024-04-20

Cancers

Abstract:PIPAC is a new and promising technique for the intraperitoneal administration of chemotherapy. It can be used in patients with various peritoneal cancer metastases. It is mainly a palliative treatment, but there is some neoadjuvant treatment potential. We have operated on 41 patients with various intra-abdominal cancers. PIPAC was performed every 6 weeks. The indication was extension of peritoneal carcinomatosis beyond the criteria for cytoreductive surgery and HIPEC. The effect was evaluated according to the peritoneal cancer index, the peritoneal regression grading score and the amount of ascites. Complications were classified according to the Clavien-Dindo system. We have performed 100 PIPAC procedures. There were two major complications, classified as Clavien Dindo III (2%). The number of procedures varied from 1 to 6. Five patients switched to cytoreductive surgery and HIPEC, and one was indicated for the watch and wait strategy due to total regression according to PRGS. Three patients are still continuing treatment. The others stopped treatment mainly because of progression of the disease and loss of metastases. We observed a reduction in ascites production soon after PIPAC application. PIPAC is a safe and well-tolerated treatment modality. It is mainly a palliative treatment that can improve the quality of life by reducing the production of ascites, but in about 10% of cases, it can reduce the extent of the disease and allow for further radical treatment.

oncology
Nivolumab in Combination with Gemcitabine and Cisplatin for Advanced Unresectable or Metastatic Biliary Tract Cancers: Results from a Single Center, Single-Arm, Phase I Study

Kaichao Feng,Qian Mei,Yang Liu,Qingming Yang,Liang Dong,Jiejie Liu,Xiang Li,Weidong Han

DOI: https://doi.org/10.2139/ssrn.3399608

2019-01-01

Abstract:Background: Current first-line chemotherapy for advanced unresectable or metastatic biliary tract cancers has limited efficacy. We assessed the safety and activity of anti-programmed death 1 (anti-PD-1) antibody nivolumab in combination with gemcitabine plus cisplatin in patients with advanced unresectable or metastatic biliary tract cancers. Methods: This study was a single-center, single-arm, open-label, phase I trial. Eligible patients received a maximum of six cycles combination therapy of gemcitabine (1000mg/m2) and cisplatin (75mg/m2) plus nivolumab (3mg/kg) every 3 weeks. Responsive patients switched to maintenance therapy with nivolumab plus gemcitabine or nivolumab alone. The primary objective was to assess the safety and progression free survival at 6 months. Between May 16, 2017, and July 31, 2018, 32 eligible patients were enrolled, and 27 response-evaluable patients received a median of 4 cycles (IQR, 3-6) combination therapy. The most common grade 3 or higher adverse events were thrombocytopenia (56%), and neutropenia (22%). 15 (55.6%) patients achieved objective response, including 5 (18.6%) complete response and 10 (37%) partial response, the disease control rate was 92.6%. At data cutoff, median progression free survival was 6.1 months (95% CI, 3.4 -8.2), and progression free survival at 6 months was 51.9 % (95% CI, 31.9-68.6). Median overall survival was 12.5 months (95% CI, 5.0-NR), the 12-month overall survival rate were 54% (95% CI, 33.1- 70.9). Treatment cycles (≥4) could predict better progression free survival and overall survival (HR 0.595, [95% CI, 0.398-0.89], p=0.012). Baseline percentage of CD3+ cells, increase of IFNγ+CD8+ cells, and decrease of IL-2, IL-18, soluble FasL and CCL2 in peripheral blood were biomarkers in predicting response. Interpretation: Nivolumab in combination with gemcitabine and cisplatin had a manageable safety profile and promising antitumor efficacy in advanced unresectable or metastatic biliary tract cancers. Trial Registration: (NCT03311789). Funding Statement: This research was supported by the grants from the Natural Science Foundation of China (No. 81830002 and 31870873 to WDH, No. 81773248, 81572914 to Qian Mei), the National Key Research and Development Program of China (No. 2016YFC1303501 and 2016YFC1303504 to WDH). Declaration of Interests: There was no commercial funding in this study. All authors declared no competing interests. Ethics Approval Statement: The study protocol was approved by the institutional ethics committee and conducted in accordance with international standards of good clinical practice. Written informed consent based on Declaration of Helsinki principles was provided by patients or their representatives before study entry.
Number of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Treatments is Associated with Longer Survival

Ran Orgad,Naoual Bakrin,Isabelle Bonnefoy,Laurent Villeneuve,Mohamad Alyami,Omar Alhadeedi,Olivier Glehen,Vahan Kepenekian

DOI: https://doi.org/10.1097/sla.0000000000006447

IF: 13.787

2024-07-23

Annals of Surgery

Abstract:Objective: To analyze the reasons for stopping pressurized intraperitoneal aerosolized chemotherapy (PIPAC) delivered for unresectable peritoneal surface malignancies (PSM) and to determine survival in a large patient cohort of an experienced PIPAC center. Background: PIPAC alone or combined with systemic chemotherapy was developed to palliatively treat unresectable PSM. Safety, tolerance and promising survival results were already reported, but the reasons for stopping treatment remain unclear and the influence of the number of PIPAC procedures on prognosis has not been evaluated. Methods: A retrospective analysis of PIPAC procedures from a prospectively maintained single institution PSM database was conducted from January 2016 to January 2023. Results: A total of 346 patients underwent 1200 PIPAC treatments in the defined time period. Two-thirds of the patients completed 3 or more PIPAC procedures, and 2 patients had more than 15 treatment procedures. Reasons for PIPAC cessation were disease progression or complication (56%), reorientation to a potential curative procedure (19%), surgical complications of the procedure (13%), death between procedures (8%) and patient request (3%). PSM origin and receiving 3 or more PIPAC treatments were independently correlated with better survival in the overall population, in the group of ultimately unresectable PSM and after propensity score weighting. Conclusion: The main reason for stopping PIPAC treatment in palliative management of PSM is disease progression. When 3 or more PIPAC procedures can be delivered in combination to systemic chemotherapy, survival is significantly improved. Its use should be validated by prospective studies.

surgery
Phase I PIANO trial-PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomes

R Sundar,D K A Chia,J J Zhao,A R Y B Lee,G Kim,H L Tan,A Pang,A Shabbir,W Willaert,H Ma,K K Huang,T Hagihara,A L K Tan,C-A J Ong,J S M Wong,C J Seo,R Walsh,G Chan,S W Cheo,C C C Soh,E Callebout,K Geboes,M C H Ng,J H Y Lum,W Q Leow,S Selvarajan,A Hoorens,W H Ang,H Pang,P Tan,W P Yong,C S L Chia,W Ceelen,J B Y So

DOI: https://doi.org/10.1016/j.esmoop.2024.103681

IF: 6.883

2024-09-16

ESMO Open

Abstract:Introduction: Pressurized intraperitoneal aerosol chemotherapy-oxaliplatin (PIPAC-OX) induces direct DNA damage and immunogenic cell death in patients with gastric cancer peritoneal metastases (GCPM). Combining PIPAC-OX with immune checkpoint inhibition remains untested. We conducted a phase I first-in-human trial evaluating the safety and efficacy of PIPAC-OX combined with systemic nivolumab (NCT03172416). Methods: Patients with GCPM who experienced disease progression on at least first-line systemic therapy were recruited across three centers in Singapore and Belgium. Patients received PIPAC-OX at 90 mg/m2 every 6 weeks and i.v. nivolumab 240 mg every 2 weeks. Translational studies were carried out on GCPM samples acquired during PIPAC-OX procedures. Results: In total, 18 patients with GCPM were prospectively recruited. The PIPAC-OX and nivolumab combination was well tolerated with manageable treatment-related adverse events, although one patient suffered from grade 4 vomiting. At second and third PIPAC-OX, respectively, the median decrease in peritoneal cancer index (PCI) was -5 (interquartile range: -12 to +1) and -7 (interquartile range: -6 to -20) and peritoneal regression grade 1 or 2 was observed in 66.7% (6/9) and 100% (3/3). Translational analyses of 43 GCPM samples revealed enrichment of immune/stromal infiltration and inflammatory signatures in peritoneal tumors after PIPAC-OX and nivolumab. M2 macrophages were reduced in treated peritoneal tumor samples while memory CD4+, CD8+ central memory and naive CD8+ T-cells were increased. Conclusions: The first-in-human trial combining PIPAC-OX and nivolumab demonstrated safety and tolerability, coupled with enhanced T-cell infiltration within peritoneal tumors. This trial sets the stage for future combinations of systemic immunotherapy with locoregional intraperitoneal treatments.
Erratum To: Cytotoxic Effect of Different Treatment Parameters in Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) on the in Vitro Proliferation of Human Colonic Cancer Cells

Veria Khosrawipour,David Diaz-Carballo,Ali-Haydar Acikelli,Tanja Khosrawipour,Thomas Albert Falkenstein,Dan Wu,Jürgen Zieren,Urs Giger-Pabst

DOI: https://doi.org/10.1186/s12957-017-1155-y

2017-01-01

World Journal of Surgical Oncology

Abstract:Pressurized intraperitoneal aerosol chemotherapy (PIPAC) has been recently reported as a new approach for intraperitoneal chemotherapy (IPC). By means of a patented micropump, the liquid chemotherapy is delivered into the peritoneal cavity as an aerosol which is supposed to achieve "gas-like" distribution. However, recent data report that the fraction of the submicron aerosol (gas-like) is less than 3 vol% of the total amount of aerosolized chemotherapy. Until today, possible modifications of treatment parameters during PIPAC with the aim of improving therapeutic outcomes have not been studied yet. This study aims to establish an in vitro PIPAC model to explore the cytotoxic effect of the submicron aerosol fraction and to investigate the impact of different application parameters on the cytotoxic effect of PIPAC on human colonic cancer cells.An in vitro model using HCT8 colon adenocarcinoma wild-type cells (HCT8WT) and multi-chemotherapy refractory subline (HCT8RT) was established. Different experimental parameters such as pressure, drug dosage, time exposure, and system temperature were monitored in order to search for the conditions with a higher impact on cell toxicity. Cell proliferation was determined by means of colorimetric MTT assay 48 h following PIPAC exposures.Standard operational parameters applied for PIPAC therapy depicted a cytotoxic effect of the submicron aerosol fraction generated by the PIPAC micropump. We also observed that increasing pressure significantly enhanced tumor cell toxicity in both wild-type and chemotherapy-resistant cells. A maximum of cytotoxicity was observed at 15 mmHg. Pressure >15 mmHg did not show additional cytotoxic effect on cells. Increased oxaliplatin dosage resulted in progressively higher cell toxicity as expected. However, in resistant cells, a significant effect was only found at higher drug concentrations. Neither an extension of exposure time nor an increase in temperature of the aerosolized chemotherapy solution added an improvement in cytotoxicity.In this in vitro PIPAC model, the gas-like PIPAC aerosol fraction showed a cytotoxic effect which was enhanced by higher intra-abdominal pressure with a maximum at 15 mmHg. Similar findings were observed for drug dose escalation. A phase I dose escalation study is currently performed at our institution. However, increasing the intra-abdominal pressure might be a first and simple way to enhance the cytotoxic effect of PIPAC therapy which needs further clinical investigations.
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in combination with FOLFOX chemotherapy as a first-line treatment for gastric cancer patients with peritoneal metastases: single-arm phase II study

Martynas Luksta,Augustinas Bausys,Klaudija Bickaite,Rokas Rackauskas,Marius Paskonis,Raminta Luksaite-Lukste,Anastasija Ranceva,Rokas Stulpinas,Birute Brasiuniene,Edita Baltruskeviciene,Nadezda Lachej,Rasa Sabaliauskaite,Rimantas Bausys,Skaiste Tulyte,Kestutis Strupas

DOI: https://doi.org/10.1186/s12885-023-11549-z

IF: 4.638

2023-10-26

BMC Cancer

Abstract:Gastric cancer (GC) remains among the most common and most lethal cancers worldwide. Peritoneum is the most common site for distant dissemination. Standard treatment for GC peritoneal metastases (PM) is a systemic therapy, but treatment outcomes remain very poor, with median overall survival ranging between 3-9 months. Thus, novel treatment methods are necessary. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is the most novel technique for intraperitoneal chemotherapy. Some preliminary data suggest PIPAC can achieve improved long-term outcomes in patients with GC PM, especially when used in combination with systemic chemotherapy. However, there is a lack of data from well-design prospective studies that would confirm the efficacy of PIPAC and systemic therapy combination for first-line treatment.

oncology
A Single-Arm Phase II Study of Nab-Paclitaxel Plus Gemcitabine and Cisplatin for Locally Advanced or Metastatic Biliary Tract Cancer.

Ting Liu,Qing Li,Zhen Lin,Chunhua Liu,Wei Pu,Shasha Zeng,Jun Lai,Xuebin Cai,Lisha Zhang,Shuyang Wang,Miao Chen,Wei Cao,Hongfeng Gou,Qing Zhu

DOI: https://doi.org/10.4143/crt.2023.726

IF: 5.036

2024-01-01

Cancer Research and Treatment

Abstract:Purpose Patients with advanced biliary tract cancer (BTC) have a poor survival. We aim to evaluate the efficacy and safety of nabpaclitaxel plus gemcitabine and cisplatin regimen in Chinese advanced BTC patients. Materials and Methods Eligible patients with locally advanced or metastatic BTC administrated intravenous 100 mg/m2 nab-paclitaxel, 800 mg/m2 gemcitabine, and 25 mg/m2 cisplatin every 3 weeks. The primary endpoint was progression -free survival (PFS). The secondary endpoints included overall survival (OS) and adverse events, while exploratory endpoint was the association of biomarkers with efficacy. Results After the median follow-up of 25.0 months, the median PFS and OS of 34 enrolled patients were 7.1 months (95% confidence interval [CI], 5.4 to 13.7) and 16.4 months (95% CI, 10.9 to 23.6), respectively. The most common treatment -related adverse events at >= 3 grade were neutropenia (26.5%) and leukopenia (26.5%). Survival analyses demonstrated that carcinoembryonic antigen (CEA) levels could monitor patients' survival outcomes. A significant increase in the number of infiltrating CD4+ cells (p=0.008) and a decrease in programmed death-1-positive (PD -1+) cells (p=0.032) were observed in the response patients. Conclusion In advanced BTC patients, nab-paclitaxel plus gemcitabine and cisplatin regimen showed therapeutic potential. Potential prognostic factors of CEA levels, number of CD4+ cells and PD -1+ cells may help us maximize the efficacy benefit.
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Gastric Cancer Peritoneal Metastases: Results from the Lithuanian PIPAC Program

Martynas Luksta,Augustinas Bausys,Neda Gendvilaite,Klaudija Bickaite,Rokas Rackauskas,Marius Paskonis,Raminta Luksaite-Lukste,Anastasija Ranceva,Rokas Stulpinas,Birute Brasiuniene,Edita Baltruskeviciene,Nadezda Lachej,Juste Bausiene,Tomas Poskus,Rimantas Bausys,Skaiste Tulyte,Kestutis Strupas

DOI: https://doi.org/10.3390/cancers16172992

2024-08-30

Cancers

Abstract:Background: Peritoneal metastases (PM) of gastric cancer (GC) are considered a terminal condition, with reported median survival ranging from 2 to 9 months. Standard treatment typically involves systemic chemotherapy alone or combined with targeted therapy or immunotherapy, though efficacy is limited. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) has emerged as a novel technique for treating GC PM, although it remains an experimental treatment under investigation. This study aimed to summarize the outcomes of GC PM treatment with PIPAC from the Lithuanian PIPAC program. Methods: All patients who underwent PIPAC for GC PM at Vilnius University Hospital Santaros Klinikos between 2015 and 2022 were included in this retrospective study. The safety of PIPAC was assessed by postoperative complications according to the Clavien–Dindo classification. Efficacy was evaluated based on the peritoneal carcinomatosis index (PCI), ascites dynamics throughout the treatment, and long-term outcomes. Results: In total, 32 patients underwent 71 PIPAC procedures. Intraoperative and postoperative morbidity related to PIPAC occurred after three (4.2%) procedures. Following PIPAC, there was a tendency towards a decrease in median PCI from 10 (Q1 3; Q3 13) to 7 (Q1 2; Q3 12), p = 0.75, and a decrease in median ascites volume from 1300 mL (Q1 500; Q3 3600) at the first PIPAC to 700 mL (Q1 250; Q3 4750) at the last PIPAC, p = 0.56; however, these differences were not statistically significant. The median overall survival after PM diagnosis was 12.5 months (95% CI 10–17), and the median survival after the first PIPAC procedure was 5 months (95% CI 4–10). Conclusions: PIPAC is a safe and feasible treatment option for GC PM; however, well-designed prospective studies are needed to fully assess its efficacy.

oncology
Efficacy Analysis of Nivolumab in Combination with Gemcitabine and Cisplatin in Patients with Unresectable or Metastatic Biliary Tract Cancers

Kaichao Feng,Yang Liu,Qingming Yang,Liang Dong,Jiejie Liu,Xiang Li,Qian Mei,Weidong Han

DOI: https://doi.org/10.2139/ssrn.3473286

2019-01-01

Abstract:Background: Current chemotherapy for advanced biliary tract cancers has limited efficacy. This study aimed to determine the efficacy and safety of nivolumab in combination with gemcitabine and cisplatin and biomarkers for predicting response and prognosis. Methods: In this open-label, single-arm, phase Ⅱ trial, enrolled patients received gemcitabine 1000mg/m2 on day 1 and d 5, followed by cisplatin 75mg/m2 on day 1 and nivolumab 3mg/kg on day 3 in every 3-week treatment cycle. Responsive patients switched to maintenance therapy after a maximum of six cycles combination therapy. The primary outcome was objective response. Secondary outcomes included safety, disease control, progression free survival and overall survival. Findings: Between November 16, 2017, and December 31, 2018, 27 of 32 enrolled patients received a median of 4 cycles (IQR, 3-6) combination therapy with a median follow-up of 12.8 (95% CI, 10.8-14.8) months. 15 (55.6%) patients achieved objective response and the disease control was 92.6%. 2 of 6 (33.3%) response evaluable patients previously treated with gemcitabine- or cisplatin-based chemotherapy achieved 1 complete response and 1 partial response.13 of 21 chemotherapy-naive patients (61.9%) achieved objective response. Median progression free survival was 6.1 months (95% CI, 3.4 -8.2), and progression free survival at 6-month was 51.9 % (95% CI, 31.9-68.6). Median overall survival was 12.5 months (95% CI, 5.0-NR), and overall survival at 12-month was 54% (95% CI, 33.1- 70.9). The most common grade 3 or higher adverse events were thrombocytopenia (56%), and neutropenia (22%). PD-L1 was invalid for predicting response and prognosis. MSI and Fitness could predict response. TNB, sFASL and IFN-γ in serum may predict prognosis. Interpretation: Nivolumab in combination with gemcitabine and cisplatin had promising efficacy and manageable safety profile in unresectable or metastatic biliary tract cancers. Clinical Trial Registration: (NCT03311789). Funding Statement: This research was supported by the grants from the Natural Science Foundation of China (No. 81830002 and 31870873 to WDH, No. 81773248, 81572914 to Qian Mei), the National Key Research and Development Program of China (No. 2016YFC1303501 and 2016YFC1303504 to WDH). Declaration of Interests: There was no commercial funding in this study. All authors declared no competing interests. Ethics Approval Statement: The study protocol was approved by the institutional ethics committee and conducted in accordance with international standards of good clinical practice. Written informed consent based on Declaration of Helsinki principles was provided by patients or their representatives before study entry.
Efficacy and safety of intraperitoneal chemotherapy for pancreatic cancer

Dorsa Safari,Mohammad Fakhrolmobasheri,Saeed Soleymanjahi

DOI: https://doi.org/10.1186/s12893-024-02526-9

2024-10-05

BMC Surgery

Abstract:Pancreatic cancer is a highly aggressive cancer with unfavorable prognosis despite the therapeutic interventions. Intraperitoneal chemotherapy has recently shown potential outcomes in the presence of peritoneal metastases. However, a consensus is still lacking on different methods for intraperitoneal chemotherapy in pancreatic cancer. A variety of drugs and doses via three types of intraperitoneal chemotherapy have been studied. The prognosis and treatment strategies for pancreatic ductal adenocarcinoma (PDAC) will be significantly influenced by peritoneal dissemination and resectability of the macroscopic disease. Normothermic intraperitoneal chemotherapy (NIPEC) has been used for the treatment of peritoneal metastases of pancreatic carcinomas. Intraperitoneal chemotherapy is often combined with systemic therapies or surgical procedures which may lead to favorable combination therapies such as cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a relatively new approach that provides a homogenous and deep penetration of the chemotherapy into the peritoneum by producing aerosols. The present study aims to review the literature for recent evidence on intraperitoneal chemotherapy in pancreatic cancer.

surgery
Food, the law and public health: three models of the relationship.

T. Lang

DOI: https://doi.org/10.1016/J.PUHE.2006.07.013

IF: 4.984

2006-10-01

Public Health

Abstract:
A phase II study of liposomal irinotecan-based chemotherapy with or without PD-1 inhibitor in patients with unresectable locally advanced or metastatic biliary tract cancer.

Jieer Ying,Xiangdong Cheng,Qi Xu,Jingjing Li,Yiwen Zhuo,Yanping Liu,Jing Yuan

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.e15077

IF: 45.3

2024-06-01

Journal of Clinical Oncology

Abstract:e15077 Background: Clinical outcomes for advanced biliary tract cancer (BTC) patients (pt) progressed on first-line therapy remain dismal. Liposomal irinotecan (LI) (HE072) is a formulation encapsulating I in a lipid bilayer vesicle and was approved in China in September 2022. It was used with 5-fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic pancreatic cancer progressing on gemcitabine treatment. We conducted an phase II study to investigate HE072 in combination with 5-FU and LV with or without a novel PD-1 inhibitor SG001 in patients with advanced BTC progressed on prior gemcitabine-based chemotherapy. Methods: This is a multi-center, non-randomized, open label phase II study in pts with unresectable locally advanced or metastatic BTC. Key inclusion factors were ECOG PS 0-1, prior gemcitabine-based chemotherapy, evidence of disease progression with at least one measurable lesion and adequate haematological/organ function. Key exclusion factor was brain metastases. Pts were treated with liposomal irinotecan (70 mg/m 2 ) plus LV (400 mg/m 2 f) and 5-FU (2400 mg/m 2 ) with or without SG001 (240mg) IV every 2 weeks for up to 2 years in absence of disease progression or unacceptable toxicity. Tumor assessments based on RECIST 1.1 were performed every 6 weeks by investigators. Primary endpoint was objective response rate (ORR). Secondary endpoints include progression free survival (PFS), overall survival (OS), disease control rate (DCR) and safety. Results: As of April 25, 2023, 17 BTC pts were enrolled into liposomal irinotecan-based chemotherapy arm (n = 7) and liposomal irinotecan-based chemotherapy plus SG001 arm (n = 10). ORR and DCR were 14.3% and 71.4% for chemotherapy arm, 20% and 40% for chemotherapy+ SG001 arm. Median OS and PFS for chemotherapy arm was 11.5(95% CI, 3.9-NE) and 4.2(95% CI, 1.4-NE) months, and for chemotherapy+PD-1 arm was 15.3 (95% CI, 3.6-17.0) and 3.8(95% CI, 1.4-6.9) months. All pts experienced treatment-related adverse events (TRAEs). The incidence of grade≥3 TRAEs was 58.8%(10/17), which occurred in 57% (4/7) of pts treated in chemotherapy arm vs 60% (6/10) in chemotherapy+SG001 arm. Among all patients, the most frequent grade ≥3 TRAEs were fatigue (29.4%), neutropenia (23.5%) and leukopenia (23.5%). One grade 4 TRAE leading to dose reduction in liposomal irinotecan was febrile neutropenia in chemotherapy arm. There were no treatment-related deaths. Conclusions: These preliminary results suggested that liposomal irinotecan plus 5-FU and LV was well-tolerated and showed promising and durable clinical activity in advanced BTC pts progressed on first-line treatment. Combined use of SG001 further improved clinical outcome in these pts without increased toxicity. Combination of liposomal irinotecan, 5-FU, LV and PD-1 inhibitor is a treatment strategy which is worthy of further exploration.

oncology
Acute febrile toxic reaction in patients with refractory rheumatoid arthritis who are receiving combined therapy with methotrexate and azathioprine.

Ricardo Blanco,V. Martínez-Taboada,M. González-Gay,J. Armona,José L. Fernández-Sueiro,M. Gonzalez-vela,Vicente Rodríguez-Valverde

DOI: https://doi.org/10.1002/ART.1780390619

1996-06-01

Arthritis & Rheumatism

Abstract:OBJECTIVE To assess the frequency and clinical features of an acute febrile toxic reaction (AFTR) in patients with refractory rheumatoid arthritis (RA) receiving combined therapy with methotrexate (MTX) and azathioprine (AZA). METHODS A cohort of 43 RA patients being treated with MTX/AZA combination therapy were studied. In all of them, RA had been refractory to single-therapy disease-modifying antirheumatic drugs. We analyzed the frequency and clinical features of AFTR, which consisted mainly of the development of fever, leukocytosis, and cutaneous leukocytoclastic vasculitis when AZA was added to the MTX regimen. RESULTS Four of the 43 patients (9.3%) who had been receiving long-term, well-tolerated treatment with MTX (mean +/- SD 375.5 +/- 159.5 days, range 227-561 days) developed AFTR shortly (mean +/- SD 25.7 +/- 13.6 days, range 17-46 days) after the addition of AZA to the regimen. The AFTR resolved rapidly (3 +/- 1.4 days) after discontinuation of AZA and MTX. In 2 cases, rechallenge with AZA and MTX was linked to a new flare of AFTR. CONCLUSION The knowledge of this side effect is particularly important because it mimics a severe infectious complication related to immunosuppressive therapy, and because rechallenge can produce severe toxicity. Most of the new combined therapies for RA do not seem to be more toxic than single-drug treatment. Nevertheless, clinicians should be aware of a possible increase in side effects due to drug interactions or some other unidentified mechanism.

Studies on the paradoxical phase of sleep in the cat.

Pressurized Intraperitoneal Aerosol Chemotherapy for Peritoneal Carcinomatosis in Colorectal Cancer Patients: A Systematic Review of the Evidence

PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases

Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) experience in patients with recurrent low grade serous ovarian carcinoma (LGSOC): sub-cohort report of phase 1 clinical trial

Feasibility, Efficacy and Safety—A Systematic Review and Meta-Analysis

Impact of PIPAC-Oxaliplatin on Functional Recovery, Good Days, and Survival in a Refractory Colorectal and Appendiceal Carcinomatosis: Secondary Analysis of the US PIPAC Collaborative Phase 1 Trial

PIPAC in patients with peritoneal metastases from gastrointestinal tract (PIPOX01): An open label, non-comparative phase 1/2 dose escalation and expansion trial

PIPAC Pharmacologic and Clinical Data

Pressurised Intraperitoneal Aerosolised Chemotherapy—Results from the First Hundred Consecutive Procedures

Nivolumab in Combination with Gemcitabine and Cisplatin for Advanced Unresectable or Metastatic Biliary Tract Cancers: Results from a Single Center, Single-Arm, Phase I Study

Number of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Treatments is Associated with Longer Survival

Phase I PIANO trial-PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomes

Erratum To: Cytotoxic Effect of Different Treatment Parameters in Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) on the in Vitro Proliferation of Human Colonic Cancer Cells

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in combination with FOLFOX chemotherapy as a first-line treatment for gastric cancer patients with peritoneal metastases: single-arm phase II study

A Single-Arm Phase II Study of Nab-Paclitaxel Plus Gemcitabine and Cisplatin for Locally Advanced or Metastatic Biliary Tract Cancer.

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Gastric Cancer Peritoneal Metastases: Results from the Lithuanian PIPAC Program

Efficacy Analysis of Nivolumab in Combination with Gemcitabine and Cisplatin in Patients with Unresectable or Metastatic Biliary Tract Cancers

Efficacy and safety of intraperitoneal chemotherapy for pancreatic cancer

Food, the law and public health: three models of the relationship.

A phase II study of liposomal irinotecan-based chemotherapy with or without PD-1 inhibitor in patients with unresectable locally advanced or metastatic biliary tract cancer.

Acute febrile toxic reaction in patients with refractory rheumatoid arthritis who are receiving combined therapy with methotrexate and azathioprine.